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Summary Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme fordegradation of 5-fluorouracil (5-FU). DPD activity is highly
variable in liver and peripheral mononuclear cells (PMNCs) and it has not been well studied in human tumours. Characterization of DPD in
colorectal cancer is of clinical interest through its role in the regulation of 5-FU, the main chemotherapeutic agent used in this disease.
Therefore, DPD activity was analysed in colorectal tumour and adjacent normal tissue from 63 patients, including three liver metastasis. DPD
activity was highly variable in all tissues studied (coefficient ofvariation 43-61%) and was higher in normal tissue than in tumour. The tumour-
normal activity ratio ranged from 0.19 to 3.32 (median 0.76). PMNC DPD activity was available for 57 patients and was correlated with tumour
activity (r5 = 0.29, P< 0.001). A higher correlation was observed between PMNCs and tumour samples that were both obtained in the morning
(r, = 0.49), consistent with circadian variation in DPD activity. Normal tissue DPD activity was not correlated with either tumour (r5 = 0.11) or
PMNC activity (rs = -0.06). This study provides the first analysis of DPD activity in colorectal cancer and illustrates the large degree of
variation in tumour activity. The tumour-normal activity ratio results suggest that elevated tumour DPD can play a role in 5-FU resistance
through increased inactivation in tumour cells, but is an uncommon event in colorectal tumours. The results support the use of PMNCs for
monitoring tumour DPD activity, particularly when circadian variation is taken into account. As a large degree of the variation in tumour DPD
activity is not explained by PMNC activity, more accurate alternatives are needed before DPD activity can be used for targeting 5-FU therapy.
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5-Fluorouracil (5-FU) is commonly used in the treatment of
gastrointestinal, head and neck, and breast tumours. 5-FU is itself
inactive and requires intracellular conversion to form cytotoxic
nucleotides. Severalcellulartargets forfluoropyrimidines havebeen
well characterized, including inhibition of thymidylate synthase
(TS) by FdUMP and false-base incorporation into RNA or DNA.
Most investigations into cellular resistance factors regulating 5-FU
activity have focused on alterations in TS levels and reduced folate
pools, the required cofactor for binding dUMP to TS (Wang et al,
1993; Johnston etal, 1995). However, mostofan administered 5-FU
dose undergoes metabolism to an inactive species through a three-
enzyme process, which is initiated and rate limited by dihydro-
pyrimidine dehydrogenase (DPD; EC 1.3.1.2). After a bolus
injection of5-FU, 80% is degraded via DPD 24 h after administra-
tion (Heggie et al, 1987). Studies of 19F-NMR spectroscopy in mice
bearing colon tumours found that catabolites made up 51% of
labelled drug in the tumour, compared with 26% for the anabolic
products (Kamm et al, 1994). Therefore, catabolism of 5-FU may
represent a major determinant of5-FU anti-tumour activity. Indeed,
several DPD inhibitors are under evaluation as modulators of5-FU
therapy (Cao et al, 1994; Naguib et al, 1994).
DPD activity is found in most tissues, with the highest content in
liver and PMNCs (Ho et al, 1984; McMurrough and McLeod,
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1996). PMNCs are used as an easily accessible surrogate tissue for
assessing in vivo DPD activity, and a high degree of variation in
activity is observed in the general population (up to 20-fold range)
(McMurrough and McLeod, 1996). There is a paucity of informa-
tion on the correlation between PMNCs and tumour DPD activity
to assess the use of this measure for predicting tumour catabolic
capacity for 5-FU. 5-FU is usually well tolerated, however patients
with low or undetectable DPD activity are at risk of severe, even
life-threatening toxicity, such as pancytopenia, mucositis and neuro-
logical disorders (Harris et al, 1991; Wei etal, 1996). Family studies
have shown that DPD deficiency demonstrates an autosomal reces-
sivepattern ofinheritance (Harris et al, 1991; Wei et al, 1996).
Little is known about DPD activity in human tumours. Analysis
of human tumour xenografts found a 28-fold range in DPD
activity among 19 solid tumours and haematopoietic malignancies
(Naguib et al, 1985). DPD activity in the tumour xenografts was
generally lower than that in human liver and was similar to
that observed in other human organ tissues. DPD activity has also
been measured in surgical specimens from 56 head and neck
cancer patients before administration of 5-FU-based therapy
(Etienne et al, 1995). Tumour DPD activity ranged from 13 to
193 pmol min-m mg-' protein, and the median ratio of tumour to
adjacent normal tissue was 1.04 (0.26-6.59). The tumour-normal
ratio was higher in the non-responding patients than those
achieving apartial or complete response, suggesting that increased
intratumoral catabolism can influence tumour response to 5-FU
therapy by decreasing the amount of drug available to form
cytotoxic nucleotides (Etienne et al, 1995).
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Table 1 DPD activity in colorectal cancer
n Median activity Range
Colorectal tumour 60 54.7a 27.9-206.9
Normal mucosa 60 73.5 33.6-375.0
Liver metastasis 3 109.8 87.9-219.6
Normal liver 3 211.7 89.4-241.3
WBC 57 197.0 74.0-491.1
Colorectal cell lines 5 12.8 6.8-26.8
apmol min-' mg-' protein.
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Figure 1 Variation in dihydropyrimidine dehydrogenase activity in colorectal
tumour and human colon carcinoma cell lines. 0, Liver metastasis samples
(n = 3)
In the current study the activity of DPD was measured in the
tumour, adjacent normal tissue and PMNCs of 63 patients with
colorectal cancer to assess the correlation between the various
tissues and the identification of demographic, anatomical and
pathological factors that influence enzyme activity.
MATERIALS AND METHODS
Chemicals
'4C-labelled 5-FU (54 mCi mmol-') was purchased from
Amersham International (Little Chalfont, UK). All other chemi-
cals were obtained from Sigma Chemical (Poole, Dorset, UK),
unless otherwise indicated.
Patients
Evaluation of DPD was conducted in 63 consecutive patients
undergoing surgery for colorectal cancer. The surgical procedure
was for initial resection in the majority of patients (60 of 63
patients), while three patients underwent hepatic lobectomy for
solitary colorectal metastasis. This study was approved by the
local ethical committee, and written informed consent was
obtained from all patients. Immediately afterresection, portions of
viable tumour and adjacent normal tissue (6-20 cm from tumour)
were removed by an experienced gastrointestinal pathologist and
frozen in liquid nitrogen. Tumour cellularity was scored using
a six-point scale (very low, low, low/moderate, moderate,
moderate/high, high) on haematoxylin-eosin-stained tissue
sections. Samples were then stored at - 80°C until analysis for
enzyme activity. A 20-ml heparinized blood sample was obtained
within 48 h after surgery. All blood samples were taken between
9 a.m. and 10:30 a.m., PMNCs were isolated and stored for
enzyme activity analysis as previously described (McMurrough
and McLeod, 1996). The influence of tissue DPD activity on
response to 5-FU therapy was not evaluated in this study because
ofthe number ofindividuals who received uniform post-operative
therapy within each Duke's stage.
Five human colorectal cell lines (HT-29, CACO-2, BE, DLD-1,
LoVo; kind gift of Dr Jane Plumb, University of Glasgow) were
maintained in Ham's FlO/Dulbecco's modified Eagle medium
(DMEM) with 10% fetal calf serum (Life Technologies, Paisley,
UK). Cells grown to -75% confluence were washed twice with
cold phosphate-buffered saline and dislodged from the flask into
1 ml of buffer (35 mm sodium phosphate pH 7.5 plus 10%
glycerol) with a rubber policeman. This was transferred into an
Eppendorf tube, centrifuged at 10 000g for 10 s and stored at
- 80°C until analysis (McMurrough and McLeod, 1996).
Analysis of DPD activity
Frozen tissue was weighed and homogenized in 4ml of buffer A
(35 mm potassium phosphate, pH 7.4, 2.5 mm magnesium chloride,
10 mM 2-mercaptoethanol) with 0.25 M sucrose, 1 mM amino-
ethylisothiouronium bromide, 1 mm benzamidine and 5 mM
Na2EDTA. Thehomogenate wascentrifuged at 100OOOgfor60 min
at 4°C. The cytosolic fraction was retained for use in DPD activity
assay. The cytosolic protein content was determined by the Bradford
assay (Bio-Rad, Hemel Hempstead, UK) (Bradford, 1976).
The assay was modified from a previously reported method
(McMurrough and McLeod, 1996). In brief, a reaction mixture
consisting of 250gIM NADPH, 125 gM [14C]5-FU, buffer A and
cytosol in a final volume of 125 g1 was incubated for 45 min at
37°C in a shaking water bath. The reaction was terminated by the
addition of an equal volume ofice-cold ethanol. The mixture was
stored at - 20°C for at least 30 min and subsequently centrifuged
at 1100g for 10 min. The supematant was assayed in triplicate for
5-FU catabolites using a high-performance liquid chromatography
method as previously described (McMurrough and McLeod,
1996). DPD activity was taken as the sum of all catabolite
peaks (5-fluorodihydrouracil, 5-fluoroureidopropionate, fluoro-
,B-alanine) and expressed as pmol ofproduct formed per min per
mg ofprotein (pmol min-' mg-1 protein). The assay was linear for
both sample protein content (10-150 gg, r2 = 0.98) and for length
of reaction incubation (5-60 min, r2 = 0.97). Peripheral PMNCs
and human colorectal cancer cell lines were processed and
analysed for DPD activity as previously described (McMurrough
and McLeod, 1996).
Statistical analysis
Comparison of DPD activity in matched tumour, normal and
mononuclear tissues was made using the Wilcoxon test. The rela-
tionship between activity in the three tissues from each patient as
well as the correlation between DPD activity and age was assessed
using the Spearman's ranktest. The influence ofpathological diag-
nosis, tumour stage and site of tumour was evaluated with the
Kruskal-Wallis test. Comparison of DPD activity in the various
tissues between gender or time of surgery (a.m. vs p.m.) was
performed using the Mann-Whitney test. The activity in tumour
tissue and that in cell lines were also compared using the
Mann-Whitney test.
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Figure 2 Correlation between PMNCs and tumour dihydropyrmidine
dehydrogenase activity in patients with colorectal cancer. 0, Tumour
samples obtained between 9 a.m. and 12 a.m; 0, samples obtained between
1 p.m. and 6 p.m. , Liver metastasis samples with matching PMNC
samples. Both were obtained before 12 a.m.
RESULTS
DPD activity was assessed in 63 consecutive patients (32 male, 31
female). The median patient age was 70 years and ranged from 32
to 87 years. Most ofthe tumours (36 of63) were located in the left
colon (descending, sigmoid colon), with a smaller number from
the right colon (17 of 63; caecum, ascending colon) and rectum
(8 of 63). Liver metastasis and adjacent normal liver were also
obtained from three specimens. The tumours were primarily
Duke's stage B (33 of 63) or C (21 of 63), and the majority were
moderately differentiated adenocarcinomas (47 of 63). A similar
number of surgical samples was obtained before 12 a.m. (n = 31)
and after 1 p.m. (n = 32). Adjacent normal tissue was obtained in
all cases, while PMNCs were available for DPD analysis on 57 of
63 cases.
DPD activity was detectable in all tumour, adjacent normal
tissue, PMNC and colorectal cell line samples (Table 1). DPD
activity was highly variable in tumour (% CV = 55.4), normal
colon (% CV = 60.8), PMNCs (% CV = 43.0) and cell lines (% CV
= 51.6). Activity was 3.8- and 2.8-fold higher in PMNC than in
tumour and normal tissue respectively. Tumour activity was a
median 18.4 pmol min- mg-' protein lower than adjacent normal
tissue (Wilcoxon test, P = 0.001). Neither pathological diagnosis
(Kruskal-Wallis, P = 0.27) nor Duke's stage (Kruskal-Wallis,
P = 0.35) influenced tumour DPD activity. Tumour location did
influence DPD activity, with higher activity in liver metastasis
(Kruskal-Wallis, P = 0.041; Table 1). Tumour cellularity ranged
from very low to moderate/high and was not correlated with DPD
activity. No significant correlation between normal tissue DPD
activity and anatomical location was observed. Neither age nor
gender correlated with DPD activity in tumour, normal tissue or
PMNCs. As circadian variation in DPD activity has been reported
previously (Harris et al, 1990), the influence of time of surgical
resection on enzyme activity was evaluated. No significant differ-
ences in DPD activity were observed between specimens obtained
in the morning and those obtained in the afternoon in eithertumour
(median 52.2 vs 61.5 pmol min-' mg-' protein, P = 0.09) ornormal
tissue (median 83.8 vs 72.6 pmol min-' mg-' protein, P = 0.65).
Tumour DPD activity was significantly higher than that observed
in the colorectal cell lines (Figure 1; Mann-Whitney, P = 0.0003).
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Figure 3 Correlation between dihydropyrimidine dehydrogenase activity in
colorectal tumour and adjacent normal tissue. 0, Liver metastasis samples
(n=3)
The ratio of tumour to normal tissue DPD activity was also
evaluated to assess the degree of potential inherent resistance to
fluoropyrimidine therapy through increased catabolic capacity.
The median tumour-normal activity ratio was 0.76, with a range
from 0.19 to 3.32. Only three of the specimens had a
tumour-normal ratio greater than 2. The tumour-normal ratio was
not correlated with site oftumour, Duke's stage, pathological diag-
nosis, gender, age or time ofsurgery.
As PMNC DPD activity is used for monitoring patient DPD
status, it is important to assess the use ofthis surrogate marker for
prediction of tumour DPD activity. A statistically significant, but
low-level correlation was observed between tumour and PMNC
DPD activity (P < 0.001, rs = 0.29; Figure 2). A similarcorrelation
was found between the tumour-normal tissue ratio and the PMNC
DPD activity (P < 0.001, rs = 0.22). All PMNCs were obtained
in the morning, whereas the surgical specimens were from both
morning and afternoon theatre sessions. If the analysis was
restricted to the 29 morning-resection tumour-PMNC pairs, a
higher correlation with PMNC DPD activity was observed with
both tumour (rs = 0.49) and the tumour-normal ratio (rs = 0.55).
Normal tissue DPD activity was not correlated with either tumour
(rs = 0.11; Figure 3) or PMNC activity(rs =-0.06). The correlation
between normal tissue and PMNCs was only slightly improved
when restricted to the morning-resection samples (rs = - 0.13).
DISCUSSION
This study provides the first analysis ofDPD activity in colorectal
cancer, including 60 primary tumour specimens and three from
tumour metastasis. Characterization ofDPD in colorectal cancer is
of clinical interest because of its role in the regulation of 5-FU
systemic exposure, the main chemotherapeutic agent used to treat
this disease. DPD activity was highly variable in tumour, normal
tissue and PMNCs. The degree of variation was similar in the
various tissues (% CV 43-60.8). The 7.9-fold range in tumour
DPD activity was similar to that observed in head and neck
tumours (range 13 to 193 pmol min-m mg-' protein) using a similar
tissue preparation protocol (Etienne et al, 1995). Activity in this
study was higher than that in previous reports for DPD in colon
tissue. Naguib et al (1985) evaluated eight colon cell line
xenografts using a TLC assay with [14C]uracil as the substrate and
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observed activity from 0.9 to 4.0 pmol min-1 mg-' protein. The
lower activity is more consistent with our cell line data, in which
activity was significantly lower than fresh-frozen tumour. Ho et al
(1984) found lower activity in eight colon tumours compared with
25 normal colon samples. Tumour activity was 117.5-fold lower
than that observed in human liver (Ho et al, 1984). However,
significant differences in the tissue preparation and assay method-
ology used in that study exist compared with those used in the
current report and may explain the disparity in observed colon
tissue and tumour DPD activity.
Tumour DPD activity was significantly higher than that
measured in five colorectal cancer cell lines (Figure 1, Table 1).
The range of activity in this study (6.8-26.8 pmol min-' mg-'
protein) was similar to that found in a panel of six colorectal cell
lines reported previously (< 1-95 pmol min-' mg-' protein) (Beck
et al, 1994). The low level of DPD activity observed in human
colon carcinoma cell lines suggests that down-regulation of DPD
occurs in culture. This observation is similar to that seen for the
cytochrome P450 enzymes, for which a lower level of enzyme
activity is observed after 24-48 h in vitro (Hammond and Fry,
1990). Although in vitro studies have demonstrated a contribution
of DPD in regulating the cytotoxic effect of 5-FU, the disparity
between tumour and cell line data suggests that cell lines are of
limited value for prediction of in vivo 5-FU activity.
Tumour DPD activity was a median 76% of that found in
adjacent normal tissue. This difference may contribute to the
favourable differential between anti-tumour activity and systemic
toxicity from 5-FU, in that a higher degree of 5-FU degradation
would occur in normal tissues compared with that in colorectal
tumours. The ratio of tumour-normal DPD activity for colorectal
tumours is different to that reported for head and neck tumours, for
which the median ratio was 1.04 (range 0.26-6.6) as reported by
Etienne et al (1995). Seven of42 (17%) patients had aratio greater
than 2 in head and neck tumours (Etienne et al, 1995), whereas
only 3 of 63 (5%) patients had an elevated ratio in the colorectal
tumour samples. The tumour-normal activity ratio was less than 1
in the three liver metastasis samples. Tumour DPD activity was up
to 6.6-fold greater than that in adjacent normal tissue in the head
and neck specimens (Etienne et al, 1995) and 3.3-fold greater in
the colorectal tumours. This suggests that DPD can play a role in
5-FU resistance through increased inactivation in tumour cells;
however, the data presented suggest that it is likely to only play a
minor role as a resistance mechanism in colorectal tumours. DPD
activity in both colorectal tumours and adjacent colonic mucosa
was much lower than that in human liver tissue, suggesting that
liver is the major detoxification site for 5-FU (Lu et al, 1995). The
ethical and technical difficulty in obtaining liver tissue for DPD
analysis from large numbers of patients receiving 5-FU has
impeded definitive conclusions regarding the influence of liver
DPD activity on 5-FU antitumour activity.
The differential expression ofother drug-metabolizing enzymes
in tumour and in adjacent normal tissue has also been described.
The protein expression of P450 IA, P450 3A, epoxide hydrolase
and glutathione-S-transferase a and j was higher in colorectal
tumour than in peritumoral tissues (McKay et al, 1993). Apparent
tumour specificity of P450 IBI has recently been described, with
expression in 11 of 12 colon adenocarcinomas and 0 of 10 normal
colonic tissues (Murray et al, 1997). Not all enzyme activity is
different between tumour and normal tissue. Glutathione-S-trans-
ferase Xprotein expression in colonic neoplasms is similar to that
found in adjacent colon tissue (McKay et al, 1993). DT-diaphorase
activity was 24-fold higher in lung tumour than in normal lung, but
demonstrated no significant difference between colonic tumours
and normal colon, providing a basis for selection of tumour types
on which to conduct clinical trials with bioreductive agents
(Smitskamp-Wilms et al, 1995).
PMNCs are used as a surrogate tissue for assessing in vivo DPD
activity. However, there have been very few evaluations of the
concordance between activity in PMNCs and that in other tissues.
Chazal et al (1996) evaluated the link between DPD activity in
PMNCs and that in liver concomitantly obtained in 27 patients
with a variety of diseases. A weak, but statistically significant
correlation was observed between the two tissues (r2 = 0.31, P =
0.002). The median ratio of liver-PMNC activity was 0.91 (range
0.48-1.44) (Chazal et al, 1996). The same authors state that no
significant correlation was found between activity in PMNCs and
that in head and neck tumour or in adjacent normal tissue in 20
patients, but do not provide data for this comparison (Etienne et al,
1995). In the current study, PMNC DPD activity was significantly
correlated with tumour activity. This relationship was further
improved ifanalysis was restricted to the paired samples for which
both tissues were obtained during the 9 a.m. to 12 a.m. period.
Although there was no significant difference in activity between
tumours obtained before or after 12 a.m. the statistical improve-
ment in the correlation suggests that circadian variation is an
important variable influencing the power of PMNC activity to
predict in vivo DPD activity (Harris et al, 1990). No significant
relationship was identified between normal mucosa and either
tumour or PMNC activity, regardless ofthe time ofsurgical resec-
tion. This finding is consistent with that seen in head and neck
tumours, in which no correlation between tumour and adjacent
normal tissue was observed (Etienne et al, 1995). The goodness of
fit of the regression line describing the PMNC-tissue relationship
was similar for colorectal tumours (r2 = 0.45) and liver (r2 = 0.31),
supporting in part the continued use of PMNCs for monitoring
DPD (Chazal et al, 1996). This relationship was also similarto that
described between PMNC DPD activity and 5-FU systemic clear-
ance (r2 = 0.51) (Fleming et al, 1992). However, the large degree
ofvariation in tumour activity that was unaccounted forby PMNC
activity and the identification of patients with normal PMNC
activity but very low liver DPD activity (Stephan et al, 1995)
suggest that more accurate alternatives are needed before a high
level of confidence can be placed on the widespread use of this
approach for targeting 5-FU therapy. The recent identification of
mutations in the DPD gene that encode low activity will assist in
the prospective identification of patients at high risk for toxicity,
but will not account for the large variation in DPD activity in
patients with wild-type DPD (Vreken et al, 1996; Wei et al, 1996).
Alternative approaches, such as quantitative reverse transcription
polymerase chain reaction, are feasible and may offermore insight
into the regulation ofthis protein.
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